Literature DB >> 12205071

Free and total cefazolin plasma and interstitial fluid concentrations at steady state during continuous infusion.

Grant W Howard1, Evan J Begg, Stephen T Chambers, Jane Vella Brincat, Mei Zhang, Carl M J Kirkpatrick.   

Abstract

Free and total concentrations of cefazolin were compared in plasma and interstitial fluid during continuous intravenous infusion therapy. Seven patients, median age 53 (25-74) years, were administered a constant infusion of cefazolin at a mean (+/-S.D.) dose of 3.5 g (+/-1.1) per 24 h for > or = 5 days. Four blisters were induced on the forearm of each patient for sampling of interstitial fluid. Free concentrations in plasma and interstitial fluid were similar, and correlated better than total concentrations (r(2) = 0.82, P = 0.005 versus r(2) = 0.54, P = 0.056). In all patients, the free concentrations in the interstitial fluid were at least two-fold the MIC(90) for Staphylococcus aureus.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12205071     DOI: 10.1093/jac/dkf129

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Effect of Maternal Obesity on Maternal-Fetal Transfer of Preoperative Cefazolin at Cesarean Section.

Authors:  Stephanie McKenney Groff; Wareef Fallatah; Samuel Yang; Jamie Murphy; Christopher Crutchfield; Mark Marzinke; Joanne Kurtzberg; Carlton K K Lee; Irina Burd; Azadeh Farzin
Journal:  J Pediatr Pharmacol Ther       Date:  2017 May-Jun

2.  Protein binding of cefazolin is saturable in vivo both between and within patients.

Authors:  Jane W A Vella-Brincat; Evan J Begg; Carl M J Kirkpatrick; Mei Zhang; Stephen T Chambers; Kate Gallagher
Journal:  Br J Clin Pharmacol       Date:  2007-01-12       Impact factor: 4.335

3.  Physiological modeling for indirect evaluation of drug tissular pharmacokinetics under non-steady-state conditions: an example of antimicrobial prophylaxis during liver surgery.

Authors:  Franck Lagneau; Jean Marty; Pascale Beyne; Michel Tod
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-02       Impact factor: 2.745

4.  Continuous cefazolin infusion to treat bone and joint infections: clinical efficacy, feasibility, safety, and serum and bone concentrations.

Authors:  Valérie Zeller; Frédérick Durand; Marie-Dominique Kitzis; Luc Lhotellier; Jean-Marc Ziza; Patrick Mamoudy; Nicole Desplaces
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

5.  Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy.

Authors:  J G Coen van Hasselt; Karel Allegaert; Kristel van Calsteren; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Journal:  Biomed Res Int       Date:  2014-02-03       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.